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Abstract
OBJECTIVES—Acute liver failure (ALF) is classically defined by coagulopathy and hepatic 
encephalopathy (HE); however, acute liver injury (ALI), i.e., severe acute hepatocyte necrosis 
without HE, has not been carefully defined nor studied. Our aim is to describe the clinical course 
of specifically defined ALI, including the risk and clinical predictors of poor outcomes, namely 
progression to ALF, the need for liver transplantation (LT) and death.
METHODS—386 subjects prospectively enrolled in the Acute Liver Failure Study Group registry 
between 1 September 2008 through 25 October 2013, met criteria for ALI: International 
Normalized Ratio (INR)≥2.0 and alanine aminotransferase (ALT)≥10× elevated (irrespective of 
bilirubin level) for acetaminophen (N-acetyl-p-aminophenol, APAP) ALI, or INR≥2.0, ALT≥10× 
elevated, and bilirubin≥3.0 mg/dl for non-APAP ALI, both groups without any discernible HE. 
Subjects who progressed to poor outcomes (ALF, death, LT) were compared, by univariate 
analysis, with those who recovered. A model to predict poor outcome was developed using the 
random forest (RF) procedure.
RESULTS—Progression to a poor outcome occurred in 90/386 (23%), primarily in non-APAP 
(71/179, 40%) vs. only 14/194 (7.2%) in APAP patients comprising 52% of all cases (13 cases did 
not have an etiology assigned; 5 of whom had a poor outcome). Of 82 variables entered into the 
RF procedure: etiology, bilirubin, INR, APAP level and duration of jaundice were the most 
predictive of progression to ALF, LT, or death.
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CONCLUSIONS—A majority of ALI cases are due to APAP, 93% of whom will improve rapidly 
and fully recover, while non-APAP patients have a far greater risk of poor outcome and should be 
targeted for early referral to a liver transplant center.
INTRODUCTION
Patients who develop severe acute liver injury (ALI) without preexisting chronic liver 
disease, oft en demonstrate significant liver dysfunction marked by coagulopathy (defined as 
an International normalized ratio (INR)≥1.5), and are classically designated as acute liver 
failure (ALF) when any degree of hepatic encephalopathy (HE) is present (1–3). However, 
little is known about the earlier stages of ALI where there may be significant coagulopathy, 
but no discernible HE (4). We explored this apparently milder stage of liver injury, its causes 
and the relative risk of poor outcomes, namely, progressing to ALF, receiving a liver 
transplant (LT) or dying within 3 weeks from admission to the study. To describe the clinical 
features and natural history of ALI, and to identify patients most at risk for poor outcomes, 
we proposed a new strictly defined category of ALI, specifically to capture additional 
information about subjects with severe liver injury without HE. Beginning in 2008, we 
adopted the same multicenter registry design, study sites and forms for enrolling patients 
with ALF by our Acute Liver Failure Study Group (ALFSG) to prospectively collect data 
from ALI patients in parallel to the data already being collected from classic ALF patients. 
The current report describes this newly defined ALI cohort. Using these data, we applied 
random forest (RF), to identify those with ALI at risk of progression to ALF and other poor 
outcomes.
METHODS
Study population
We prospectively studied 386 consecutive subjects who were considered to have ALI and 
who were enrolled into the NIH-funded ALFSG registry from 1 September 2008 through 25 
October 2013. After an ALFSG workshop to define ALI in the ALFSG registry, criteria 
were agreed upon and enrollment of subjects with ALI began in September 2008, from up to 
23 academic centers in the United States. ALI was defined as follows: absence of HE and, 
either:
Acetaminophen (n-acetyl-p-aminophenol, APAP) ALI:
INR≥2.0 and ALT≥10×upper limit of normal
Or
Non-acetaminophen (non-APAP) ALI:
INR≥2.0, ALT≥10×upper limit of normal, and bilirubin≥3.0 mg/dl
According to the study protocol, patients were eligible if the peak INR was>2.0 within 48 h 
of enrollment. Only patients without pre-existing chronic liver disease were eligible for 
enrollment. Etiology was determined by each study center’s principal investigator, based on 
historical, clinical, laboratory, and radiographic data, as well as liver histopathologic results, 
when available. Diagnoses of etiology (APAP/non-APAP) were established using standard 
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criteria: for APAP, a history of any acetaminophen ingestion and/or parent compound 
(acetaminophen blood level) positive, plus alanine aminotransferase “ALT”, or aspartate 
aminotransferase (AST) levels≥1,000 IU/l with bilirubin<10 mg/dl; for non-APAP, patients 
in whom acetaminophen toxicity could be reasonably excluded. If an extensive search for 
the cause of ALI was inconclusive, the etiology was recorded as Indeterminate. HE, defined 
as the presence of disorientation or asterixis, was assessed by the study site principal 
investigator at the time of enrollment and on each subsequent day that the subject was 
enrolled in the registry. If present, HE severity was classified according to the West-Haven 
criteria (5).
Data management and integrity
Written informed consent was obtained from the enrolled subjects, as they were not 
encephalopathic. Patient demographics, medical history, clinical features, and laboratory 
values were collected prospectively at study enrollment, and clinical status and laboratory 
results were also recorded serially for up to 7 days, or until discharge, death, or transplant if 
prior to 7 days. All data are managed and housed on a central server by the ALFSG 
Statistical and Data Management Center at the Medical University of South Carolina. Each 
center’s Institutional Review Board approved the study.
Statistical Analyses
Data from the 386 subjects on the day of enrollment into the study were used for the 
analyses and included the following: subject demographics (age, gender, and race), calendar 
year of enrollment and center where enrollment occurred, dates of first symptom, and onset 
of jaundice and encephalopathy, etiology of the acute illness, use of N-acetylcysteine (NAC), 
blood product transfusion, measures of systemic distress (blood pressure, heart rate, 
temperature, pH, serum lactate levels, and need for vasopressor support, mechanical 
ventilation, or renal replacement therapy), and laboratory data, including measures of liver 
injury and dysfunction (serum bilirubin, aminotransferases, albumin, and INR). Descriptive 
statistics were performed and results expressed as medians (and interquartile ranges) and n 
(%) for continuous and categorical variables, respectively. Wilcoxon rank sum and χ2 tests 
were used as appropriate, and subjects with missing data were not included in the univariate 
analyses of the variables for which data were missing. Our primary outcome was the 
composite occurrence within 21 days of enrollment of either progression to ALF, receiving a 
LT, or dying. In some instances, ALI alone led to liver transplantation or death without an 
apparent phase of ALF. Associations with a P<0.05 were considered statistically significant. 
Univariate analyses were performed using SAS (v 9.1.03 Cary, NC).
A model to predict poor outcome, i.e., ALF, LT, or death, was developed using the RF 
procedure first developed by Breiman in 2001 (6). The resulting model was then applied to 
the validation dataset of 163 subjects enrolled from November 2013 to September 2015. RF 
is a statistical method that iteratively develops decision trees, or models, using binary splits 
on predictor variables, thus providing a mechanism for estimating the probability that each 
individual ALI patient will have a poor outcome. In addition, the RF procedure provides 
information about which input variables are most important for the prediction of poor 
outcome, referred to as importance measures(7). The procedure is an alternative approach to 
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more common prediction models such as logistic regression and can be used to overcome 
the statistical obstacles of correlated predictors, non-normality of predictor variables and 
missing data(6,8,9). The method has been used previously to determine etiology in the ALF 
population using the ALFSG registry(9). RF modeling was performed using R soft ware 
version 2.15.1(8). See the Supplementary Material online for a detailed description of the 
RF procedure.
RESULTS
Patient demographics
All 386 subjects with defined ALI enrolled in the ALFSG registry during the initial study 
period were included in the analysis. Of these 386 subjects, several had an INR<2.0 at the 
time of enrollment into the study. However, they were eligible for entry into the registry 
since their peak INR was>2.0 within 48 h of enrollment. The majority were women (61%) 
and Caucasian (72%) with a median age of 38.0 (interquartile range 28.0–49.0) years (Table 
1). APAP toxicity was the most common cause of ALI, accounting for 194 (50%) cases, 
followed by 46 (12%) due to autoimmune hepatitis, and 42 (11%) considered as 
Indeterminate cases. There were 13 subjects who had not received an etiologic diagnosis at 
the time of the data analysis. On average, subjects had marked elevations of 
aminotransferase levels, with median AST 2,270 U/l (929–5,219 U/l) and ALT 2,784 U/l 
(942–5,713 U/l). Serum bilirubin (5.1 mg/dl, 2.6–15.6 mg/dl) and INR (2.4, 2.1–3.4) were 
moderately elevated as was venous ammonia (65.5 µmol/dl, 41.0–94.0 µmol/dl). Subjects 
developed symptoms on average 5 days prior (2.0–14.0 days) and the onset of jaundice on 
average 4 days prior (1.0–10.0 days), to enrolling in the study. The most common symptoms 
reported include nausea and vomiting (290/383, 76%), abdominal pain (272/383, 71%), joint 
pain (55/383, 14%), and peripheral edema (37/367, 10%). Kidney injury requiring renal 
replacement therapy was rare, occurring in only 8 subjects (2%). Overall, 68% of the 
subjects were treated with NAC at some time during hospitalization. The majority (90%) of 
APAP cases received NAC compared to 30% of the non-APAP cases. Forty-three subjects 
(11%) were transfused blood products, particularly fresh frozen plasma (FFP) that accounted 
for 88% of the transfusions.
Comparing APAP to the other ALI etiologies, there was no gender difference, but APAP 
ALI subjects were younger, 34.5 years (27 years—46 years) vs. 44 years (33 years—55 
years, P<0.001) and more frequently Caucasian than the non-APAP subjects (79 vs. 64%, 
P<0.001, Table 2). Aminotransferase levels were nearly 4-fold higher in APAP compared to 
non-APAP ALI subjects, but both bilirubin (3.2 mg/dl, 1.9–4.6 mg/dl vs. 15.7 mg/dl, 8.1– 
23.4 mg/dl, P<0.001) and phosphate (2.2 mmol/l, 1.6–3.0 mmol/l vs. 3.3 mmol/l, 2.7–4.2 
mmol/l, P<0.001) were lower. Subjects with APAP toxicity also had a shorter duration of 
symptoms (3 days, 2.0–4.0 days vs. 11 days, 6.0–24.0 days, P<0.001) and jaundice (1 day, 
1.0–2.0 days vs. 8 days, 3.0–16.0 days, P<0.001) prior to enrollment.
Outcomes
During the study period, 90/386 (23%) subjects developed one or more of the three primary 
outcomes, not all of which involved ALF (Table 3). Of these, 72/386 (19%) subjects 
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progressed to ALF, 19/386 (5%) subjects died and 44/386 (11%) underwent LT. Non-
Caucasians had a greater risk of poor outcome than whites (31 vs. 20%, P=0.026) as did 
older subjects, but there was no difference between men and women (Table 3). Those with 
disease progression also had a more protracted clinical course with a longer duration of 
symptoms (11 days vs. 4 days, P<0.001) and jaundice (8 days vs. 3 days, P<0.001) before 
admission to the study. Those who were destined for a poor outcome were significantly 
more likely to have non-APAP liver injury (40% non-APAP vs. 7.2% APAP, P<0.001). The 
worse outcomes for non-APAP ALI was primarily due to their greater risk of developing 
ALF (56/179, 31% non-APAP cases developed ALF compared to 11/194, 6% of APAP 
cases, P<0.001). Accordingly, bilirubin (17.5 mg/dl vs. 4.0 mg/dl, P<0.001), INR (2.8 vs. 
2.3, P<0.001), and lactate (3.0 mmol/l, vs. 2.0 mmol/l, P<0.001) levels were higher in 
subjects with poor outcomes, but aminotransferase levels were lower (ALT: 1,165.0 U/l vs. 
3,330.0 U/l, P<0.001; and AST: 1,450.0 U/l vs. 2,642.0 U/l, P<0.001). Subjects who 
progressed to ALF, death or LT were also more likely to be transfused blood products than 
those in whom ALI resolved (27 vs. 8%, respectively, P<0.001). Finally, 261 (68%) of 
subjects were treated with NAC during the study period; the majority (81%) were APAP 
cases. Overall, fewer patients treated with NAC progressed to ALF, died or underwent LT 
compared to subjects who did not receive NAC (19 vs. 32%, P=0.005); however, this was 
primarily driven by the large number of APAP cases nearly all of whom were given NAC, 
and their very low overall risk of doing poorly. For the non-APAP cases, there was no 
association between NAC use and outcome (Table 3).
Overall, 19/386 (5%) subjects died and 45/386 (12%) underwent LT. Of the subjects who 
died, 10/19 (53%) had progressed to ALF (Table 3) including one who underwent LT, dying 
postoperatively. Additionally, not all patients who died appeared to progress to ALF (Table 
4). Although the small number of deaths precludes detailed analysis, it did not appear that a 
specific ALI etiology was over-represented among the deaths. The deaths recorded were as 
follows: APAP toxicity (4), indeterminate (4), autoimmune hepatitis (5), hepatitis B (3), 
ischemia (2), and DILI (1). The commonest causes of death mentioned were multisystem 
organ failure (4) and progressive liver failure (4). The number of patients (by etiology) who 
underwent liver transplantation included APAP toxicity (3), autoimmune hepatitis (15), DILI 
(2), hepatitis A (2), hepatitis B (3), mushroom intoxication (2), Wilson disease (2), and 
indeterminate (13). Two transplant patients had missing etiologies.
Modeling the risk of having a poor outcome
A RF model was created to determine the risk for the primary composite outcome to occur, 
namely progressing to ALF, having a LT, or dying within 21 days of enrolling into the study 
(see the Supplementary Material for a detailed description of the RF procedure). Eighty-two 
variables were considered based on results from the univariate analyses. For calculations 
used in model building, non-APAP cases were assigned an APAP blood level of zero. To 
simplify the model without compromising predictability, a variable selection procedure 
identified the most predictive variables for inclusion in the final model: etiology, admission 
values of bilirubin, INR, acetaminophen level, and duration of jaundice prior to enrollment. 
The most important variable for determining risk of poor outcome was etiology, followed in 
order by the reported duration from onset of jaundice to study admission, acetaminophen 
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level, bilirubin, and INR. The final model yielded an overall prediction accuracy of 81% and 
an area under the receiver operating curve of 0.84, indicating overall good model 
performance. Correct predictions were made for 83% (245/296) of ALI patients who had 
resolution of their underlying liver injury and for 76% (68/90) of the ALI patients who did 
progress to ALF, received LT, or died.
The RF model was applied to the validation cohort of 163 ALI subjects. There were no 
clinical differences between the training and validation datasets (Supplementary Table 1). 
Overall accuracy for the validation dataset was 75%, with accurate predictions for 67% 
(95/141) of ALI patients who did not progress to ALF, death or LT and 88% (28/32) of ALI 
patients who did progress to ALF, death or LT. Thus, the model generally made conservative 
predictions.
Partial dependence plots allowed for analysis of the relationship between outcome and 
variables included in the RF model (data not shown). Etiologies more associated with a 
higher chance of poor outcomes than other causes were pregnancy-associated liver injury, 
autoimmune hepatitis, infection with hepatitis A or B, mushroom intoxication, Wilson 
disease, Indeterminate diagnoses, and other viruses. Aside from etiology, thresholds that 
were derived from the remaining variables and that identified the at risk subjects included 
jaundice for greater than 3 days, bilirubin level greater than 3 mg/dl, APAP level greater than 
60 mg/l or INR greater than 1.7.
DISCUSSION
The original definition of ALF, sometimes termed fulminant hepatic failure, derived from a 
review article in 1970 by Trey and Davidson (1), included the presence of HE and 
coagulopathy in patients without pre-existing liver disease. While HE is a useful clinical 
marker (10), it is also a subjective one. Our knowledge of severe liver injury has been 
derived primarily from patients with HE, whereas, to-date, there have only been a few 
studies of the outcome of severe liver injury that falls short of ALF (11–18). The current 
study satisfies that unmet need. Therefore, in an effort to further understand and expand the 
repertoire of patients with severe hepatocyte necrosis and its sequelae, we developed criteria 
for ALI without HE to include patients with advanced disease by using a higher INR 
threshold (>2.0), eliminating to some extent those who might have a milder, non-progressive 
condition. We intended to provide some unique insights into the causes and natural 
progression of a cohort of ALI patients in whom HE had not yet occurred, to better 
determine what might trigger progression to ALF, need for LT, or death within 21 days of 
study enrollment. This analysis could aid clinicians’ assessment and management of patients 
with severe liver injury who lack the crucial feature of HE.
As with ALF, the majority of ALI cases occurred in Caucasian women and was due to APAP 
toxicity. This contrasts with the 25% APAP prevalence reported recently from King’s 
College Hospital (KCH) in London UK, in a more severe version of ALI than defined here, 
as the KCH cases included both HE and non-HE patients who required Intensive Care Unit 
admission(19). Among the ALI etiologies, APAP toxicity stands out as being considered 
‘hyperacute(20),’ characterized by very short duration of symptoms (<3 days), marked 
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elevation of aminotransferases and only mildly abnormal bilirubin levels. Despite the 
severity of laboratory abnormalities, these cases appear self-limited, as recovery of ALI due 
to APAP toxicity is nearly universal—here only 7% progressed to ALF, died, or needed LT. 
Conversely, non-APAP ALI patients tend to have a longer duration of symptoms and 
jaundice with more marked elevation of bilirubin and worse overall outcomes. Accordingly, 
the probability of progressing to ALF is greater with autoimmune hepatitis, DILI, and 
indeterminate etiologies, accounting for 61% of the cases. Additionally, treating non-APAP 
ALI patients with NAC did not appear to reduce the risk of developing ALF in our 
population. Death was also not confined to those ALI patients who progressed to ALF since 
half of the patients who died did not appear to pass through that stage as shown in Table 3; 
many were listed as dying of multi-organ failure or central nervous system or other 
conditions that were specific and not necessarily associated with encephalopathy. However, 
it is possible that case report form data did not reflect the exact details of disease 
progression, and some of these cases may have actually developed ALF. Notwithstanding, 
transfer to a liver transplant center is important in all forms of ALI, but particularly so for 
non-APAP cases (of whom 40% had with poor outcomes, compared to only 7.2% of APAP 
subjects), to permit early evaluation for liver transplantation.
Using a novel, multivariable RF modeling system, we identified clinical variables associated 
with progression to ALF, need for LT, or death and created a tool to estimate this probability 
of disease progression to a poor outcome. We opted for this statistical analysis rather than 
the more conventional logistic regression modeling since RF is able to account for missing 
data and is not affected adversely by interactions in the data. The result was a model that 
provides an estimate for the probability of poor outcome with an accuracy of 81%. Several 
variables were examined: the most influential within the RF model were ALI etiology, 
duration of symptoms, and study admission blood levels of bilirubin, APAP (which is zero 
in non-APAP cases), and INR. Each of these should be readily available to clinicians, 
allowing for estimation of the risk in any hospital setting. Although the overall accuracy of 
the model in the validation set was lower than in the model creation set, the model actually 
performed better for those subjects with a poor outcome compared to those who recovered.
An added benefit of RF analysis is the ability to dichotomize the predictive variables into 
thresholds that predict the outcome, allowing for quick assessment at the bedside. These 
include jaundice for greater than 3 days, bilirubin greater than 3 mg/dl, acetaminophen level 
greater than 60 mg/l, and INR greater than 1.7 (See Supplementary Material).
Of interest is the potential risk that transfusion of blood products, particularly FFP, appeared 
to have for patients with ALI. Although having a transfusion was not determined to be a 
predictive variable for disease progression for any of the three outcomes outlined in the RF 
model, 42% of the subjects who received FFP had a poor outcome as compared to 58% of 
those who did not. The clinical justification for transfusion in each subject was not available. 
The association between FFP use and progression to ALF or other outcomes does not 
necessarily indicate that FFP is contributing to worse liver injury since it may be that the 
presence of worse liver disease prompted the clinician to use FFP. However, there is 
evidence that ALF is a hypercoagulable state and it is possible that administration of clotting 
factors enhanced intrahepatic thrombosis that contributed to impairment in liver function 
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(21,22). Further studies would be needed to determine if there is inherent risk with 
transfusion in these subjects, but prudence should be exercised with regard to transfusion, 
especially given the growing awareness that the standard hematologic and coagulation 
indices (such as the INR and platelet count) do not necessarily predict bleeding risk either in 
patients with acute (21,23–26) or chronic (23,27,28) liver diseases.
CONCLUSION
In this in-depth analysis of the natural history of ALI, according to the specific criteria we 
defined, the likelihood and risk factors for poor outcome directly or indirectly related to liver 
disease were determined. APAP toxicity (52%) was the most common cause of ALI, while 
non-APAP causes were observed to have a greater risk of poor outcome, particularly when 
compared to APAP-induced liver injury. Patients at risk of a poor prognosis were identified 
with 81% accuracy using a multivariable RF predictive model.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Patients with acute liver failure have coagulopathy and encephalopathy.
✓ Acute liver failure is associated with high mortality.
WHAT IS NEW HERE
✓ A detailed natural history study of patients with less severe acute liver injury 
prior to developing encephalopthy.
✓ Patients with acute liver injury at risk for a poor outcome can be identified 
using our prognostic score.
✓ Death in patients with acute liver injury can occur even without progression 
to acute liver failure.
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Table 1
Clinical variables of enrolled subjects with acute liver injury
Admission variables Overall population (N=386)
Age (years) 38.0 (28.0–49.0)
Gender
  Male 151 (39%)
  Female 235 (61%)
Race
  Caucasian 276 (72%)
  African American 70 (18%)
  Other   40 (10%)
Etiology of ALIa
  APAP toxicity 194 (50%)
  Autoimmune hepatitis 46 (12%)
  Indeterminate 42 (11%)
  Hepatitis A 25 (6%)
  Drug-induced liver injury 23 (6%)
  Ischemia 12 (3%)
  Other 31 (8%)
Duration of symptoms (days) 5.0 (2.0–14.0)
Duration of jaundice (days) 4.0 (1.0–10.0)
Bilirubin (mg/dl) 5.1 (2.6–15.6)
Creatinine (mg/dl) 0.9 (0.6–1.4)
AST (U/l) 2,269.5 (929.0–5,219.0)
ALT (U/l) 2,784.0 (942.0–5,713.0)
Alkaline Phosphatase (IU/ml) 117.0 (87.0–161.5)
Albumin (mg/dl) 2.9 (2.5–3.2)
INR 2.4 (2.1–3.4)
Phosphate (mmol/l) 2.7 (1.9–3.6)
Venous ammonia (µmol/dl) 65.5 (41.0–94.0)
ALI, acute liver injury; ALT, alanine aminotransferase; APAP, N-acetyl-p-amino-phenol; AST, aspartate aminotransferase; INR, International 
normalized ratio.
a
Etiology not recorded for 13 subjects.
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Table 2
Clinical variables according to ALI etiologya
Admission variables APAP
ALI (N=194)
Non-APAP
ALI (N=179) P value
b
Age (years) 34.5 (27–46) 44 (33–55) <0.001
Gender 0.14
  Male 69 (36%) 77 (43%)
  Female 125 (64%) 102 (57%)
Race <0.001
  Caucasian 154 (79%) 114 (64%)
  African American 31 (16%) 38 (21%)
  Other 9 (5%) 27 (15%)
Duration of symptoms (days) 3.0 (2.0–4.0) 11.0 (6.0–24.0) <0.001
Duration of jaundice (days) 1.0 (1.0–2.0) 8.0 (3.0–16.0) <0.001
Bilirubin (mg/dl)c 3.2 (1.9–4.6) 15.7 (8.1–23.4) <0.001
Creatinine (mg/dl) 0.9 (0.7–1.7) 0.9 (0.6–1.3) 0.20
AST (U/l) 4,506.0 (2,110.0–8,048.0) 1,331.0 (561.0–2,293.0) <0.001
ALT (U/l) 4,837.0 (2,489.0–7,880.0) 1,135.0 (653.0–2,813.0) <0.001
Alkaline phosphatase (IU/ml) 98.0 (74.0–124.0) 143.0 (110.0–193.0) <0.001
Albumin (mg/dl) 3.1 (2.7–3.3) 2.6 (2.2–2.9) <0.001
INR 2.6 (2.1–4.0) 2.3 (2.2–2.9) 0.03
Phosphate (mmol/l) 2.2 (1.6–3.0) 3.3 (2.7–4.2) <0.001
Venous ammonia (µmol/dl) 68.0 (42.0–96.0) 63.0 (41.0–83.0) 0.54
Primary outcome <0.001
Progressed to ALF only 7 (4%) 16 (9%)
Transplant only 0 (0%) 10 (6%)
Death only 3 (2%) 7 (4%)
More than one of the above 4 (2%) 40 (22%)
Alive/no transplant/no progression to ALF 180 (93%) 106 (59%)
ALI, acute liver injury; ALF, acute liver failure; ALT, alanine aminotransferase; APAP, N-acetyl-p-aminophenol; AST, aspartate aminotransferase; 
INR, International normalized ratio.
a
Etiology not recorded for 13 subjects.
bUnivariate Comparisons between APAP ALI and non-APAP ALI.
c
The definition of APAP ALI included any bilirubin level, whereas for non-APAP ALI, bilirubin>3 mg/dl was the threshold for inclusion.
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Table 3
Clinical measures and ALI outcome
N Liver recovered (N=296) Poor outcomea (N=90) P value
Age (years) 386 37.0 (28.0–48.0) 44.5 (32.0–56.0) 0.002
Gender 386 0.30
  Male 120 (41%) 31 (34%)
  Female 176 (59%) 59 (66%)
Race 386 0.062
  Caucasian 220 (74%) 56 (62%)
  African American 50 (17%) 20 (22%)
  Other 26 (9%) 14 (16%)
Etiology† 373 <0.001
  APAP 180 (63%) 14 (16%)
  Non-APAP 108 (37%) 71 (84%)
Duration of symptoms (days) 376 4.0 (2.0–9.0) 11.0 (5.0–21.0) <0.001
Duration of jaundice (days) 230 3.0 (1.0–8.0) 8.0 (2.0–16.0) <0.001
Bilirubin (mg/dl) 378 4.0 (2.2–9.5) 17.5 (8.2–24.4) <0.001
AST (U/l) 382 2,642.0 (1,038.0–6,127.0) 1,450.0 (669.0–2,584.0) <0.001
ALT (U/l) 382 3,330.0 (1,250.0–6,227.0) 1,165.0 (660.0–3,061.0) <0.001
Alkaline Phosphatase (IU/ml) 380 112.0 (81.0–148.0) 139.0 (105.0–183.0) <0.001
Albumin (mg/dl) 350 3.0 (2.6–3.3) 2.6 (2.3–2.9) <0.001
INR 368 2.3 (2.0–3.1) 2.8 (2.2–4.4) <0.001
Creatinine (mg/dl) 380 0.9 (0.6–1.4) 1.0 (0.7–1.3) 0.465
Phosphate (mmol/l) 310 2.5 (1.8–3.4) 3.1 (2.3–4.3) <0.001
Venous ammonia (μmol/dl) 112 65.5 (41.0–88.) 65.0 (41.0–114.0) 0.591
Transfusion 386 <0.001
  No 273 (92%) 66 (73%)
  Yes 23 (8%) 24 (27%)
FFP transfusion 386 16 (5%) 22 (24%) <0.001
NAC use
  Overall 386 211 (71%) 50 (56%) 0.005
  Non-APAP ALI 179 42 (39%) 33 (46%) 0.314
ALF, acute liver failure; ALI, acute liver injury; ALT, alanine aminotransferase; APAP, N-acetyl-p-aminophenol; AST, aspartate aminotransferase; 
FFP, fresh frozen plasma; IQR, interquartile range; LT, liver transplantation.
Categorical data presented as n (%) and continuous data as median (IQR).
†
Etiology not recorded for 13 subjects.
a
Poor outcome includes ALF and/or LT and/or death.
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Table 4
Characteristics of 19 ALI subjects who died within 21 days of enrollment
ALI etiology Progression
to ALF
Time from
enrollment to
death (days)
Cause of death
1. APAP No 2 Cardiac arrest
2. Hepatitis B Yes 3 Multisystem organ Failure/sepsis
3. Shock/ischemia Yes 11 Unknown
4. Autoimmune hepatitis Yes 16 Unknown
5. DILI Yes 8 Multisystem organ failure
6. APAP Yes 8 Neurological (cerebral edema)
7. Indeterminate No 1 Unknown
8. Indeterminate Yes 11 Neurological (cerebral edema)
9. APAP No 8 Pulmonary embolism
10. Autoimmune hepatitis Yes 7 Liver failure
11. Indeterminate Yes 4 Multisystem organ failure/sepsis
12. Autoimmune hepatitis No 13 Multisystem organ Failure
13. Autoimmune hepatitis Yes 4 PEA arrest
14. Shock/ischemia No 14 Multisystem organ failure
15. APAP No 10 Liver failure
16. Hepatitis B No 9 Liver failure
17. Indeterminate No 18 Unknown
18. Hepatitis B No 20 Liver failure
19. Autoimmune hepatitisa Yes 17 Intracardiac thrombosis
ALI, acute liver injury; ALF, acute liver failure; APAP, N-acetyl-p-aminophenol; DILI, drug-induced liver injury; PEA, pulseless electrical activity.
a
Patient died shortly after liver transplant.
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